Back to Newsroom

ProMIS Neurosciences to announce results in a presentation at the 2017 American Association of Neurology annual meeting

TORONTO, Ontario – April 27, 2017 – ProMIS Neurosciences (“ProMIS” or the “Company”, TSE ticker PMN.TO), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced it will present results on its recent Alzheimer’s disease (AD) therapeutic developments on Friday, April 28th at the 2017 annual meeting of the American Academy of Neurology (AAN), held in Boston, MA, from April 22-28.

“Based on our results presented at this year’s AAN annual meeting we anticipate ProMIS monoclonal antibodies (mAbs), selectively targeting toxic forms of Amyloid beta (Aβ), will demonstrate a ‘best in class’ product profile for treatment of AD”, stated Dr. Elliot Goldstein, ProMIS President and CEO. “Indeed, by virtually no binding to Aβ monomer, ProMIS mAb products should allow improved efficacy by avoiding targeting of this abundant, non-toxic form of Aβ. Similarly, by not targeting plaque which is associated with neurovascular edema (‘brain swelling’), a dose limiting adverse event, we anticipate improved safety and tolerability for our products”.